Method of treatment for ischemic heart disease

Details Method of treatment for ischemic heart disease Method of treatment for ischemic heart disease

2011-02-22

2011-02-22

Kemmerer, Elizabeth C. (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S016400, C514S021200

Reexamination Certificate

active

07893018

ABSTRACT:
The present invention provides a method of treatment for ischemic heart disease administering a scar formation accelerator containing at least one selected from SFRP2, SFRP4, Midkine, Pleiotrophin and Thymosin beta-10 as an effective ingredient to promote scar formation less fibrosis and retaining elasticity, and thereby improving cardiac function.

REFERENCES:
patent: 7294334 (2007-11-01), Michal et al.
patent: 7638128 (2009-12-01), Dzau et al.
patent: 2004/0219129 (2004-11-01), Yoshida et al.
patent: 2005/0079151 (2005-04-01), Ikematsu et al.
patent: 1579539 (2005-02-01), None
patent: 08-027021 (1996-01-01), None
patent: 2004-503602 (2004-02-01), None
patent: 2004-115413 (2004-04-01), None
patent: 2005-068122 (2005-03-01), None
patent: 2005-506279 (2005-03-01), None
patent: WO-98/35043 (1998-08-01), None
patent: WO-02/05857 (2002-01-01), None
patent: WO-02/46225 (2002-06-01), None
patent: WO-2004-113513 (2004-12-01), None
Horiba, M. et al ., “Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction,” Circulation, 2004, vol. 110, No. 17, Suppl. S, p. 106.
Christman, K. L. “Pleiotrophin induces formation of functional neovasculature in vivo,” Biochemical and Biophysical Research Communications, Jul. 2005, vol. 332, No. 4, p. 1146-1152.
Philp, D. et al., “The action binding site on thymosin β-4 promotes angiogenesis,” The FASEB Journal, 2003, vol. 17, No. 14, p. 2103-2105.
Bock-Marquette, I. et al., “Thymosin β 4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair,” Nature, 2004, vol. 432, No. 7016, p. 466-472.
Barandon, L. et al., “Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA,” Circulation, 2003, vol. 108, No. 18, p. 2282-2289.
Rattner, A. et al., “A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors,” Proceedings of the National Academy of Sciences of the United States of America, 1997, vo1,94, No. 7, p. 2859-2863.
Sumida, A. et al., “Midkine prevents the cardiac remodeling in mice after myocardial infarction and improves their long-term survival,” Circulation Journal, Mar. 2006, vol. 70, No. Suppl.l, p. 274.
Horiba, M. et al. , “Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction,” Circulation, Oct. 2006, vol. 114, No. 16, p. 1713-1720.
Letters to Nature, Nature, vol. 428, Apr. 2004, p. 668-673.
Sherwood, R. I. et al., “Isolation of Adult Mouse Myogenic Progenitors: Functional heterogeneity of Cells within and Engrafting Skeletal Muscle,” Cell, vol. 119, Issue 4, Nov. 12, 2004, pp. 543-554.
Tam SK et al., “Molecular cardiomyoplasty” potential cardiac gene therapy for chronic heart failure, J. Thorac and Cardiovasc Surgery, May 1995, 918-924 (1 sheet).
He, B. et al., “Secreted Frizzled-Related Protein 4 is Silenced by Hypermethylation and Induces Apoptosis in β-Catenin-Deficient Human Mesothelioma Cells,” Cancer Res. 65 (3), Feb. 1, 2005, p. 743-748.
Lee, J-L. et al., “Autocrine/Paracrine Secreted Frizzled-related Protein 2 Induces Cellular Resistance to Apoptosis,” J. Biol. Chem. 279 (15), 2004, 14602-14609.
Owada, K. et al., “Midkine inhibits apoptosis via extracellular signal regulated kinase (ERK) activation in PC12 cells,” J Med Dent Sci. 46(1), 1999, 45-51 (1 sheet).
Bowden, E. “Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase,” J Biol Chem. 277(39), 2002, p. 35862-35868.
Rho, S. B. et al., “The identification of apoptosis-related residues in human thymosin β-10 by mutational analysis and computational modeling,” J. Biol. Chem. 280 (40), 2005, p. 34003-34007.
Kadomatsu, K. et al., “Midkine and pleiotrophin in neural development and cancer,” Cancer Letter. Feb. 20, 2004; 204: 127-143 (1 sheet).
Mitsiadis, T. A.et al., “Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis,” Development, 121, 1995; p. 37-51.
Takada, J. et al., “Postischemic gene transfer of midkine, a neurotrophic factor, protects against focal brain ischemia,” Gene Therapy. 2005;12:p. 487-493.
Ochiai K. et al., “The role of midkine and pleiotrophin in liver regeneration,” Liver Int. 2004;24: 484-491 (1 sheets).
Obama, H. et al., “Myocardial infarction induces expression of midkine, a heparin-binding growth factor with reparative activity,” Anticancer Res. 1998; 18: 145-152 (1 sheet).
Sato, W. et al., “Midkine is involved in neutrophil infiltration into the tubulointeristitium in ischemic renal injury,” J. Immunol. 2001;167:p. 3463-3469.
International Search Report mailed on Jan. 16, 2007, issued on the PCT International Application No. PCT/JP2006/322782.
Heike Schumann et al., “Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression,” Cardiovascular Research, vol. 45, 2000, pp. 720-728.
Jonathan M. Levin, “SFRP2 expression in rabbit myogenic progenitor cells and in adult skeletal muscles,” Journal of Muscle Research and Cell Motility, vol. 22, 2001, pp. 361-369.
Supplementary European Search Report dated Jun. 10, 2010, issued in the European Patent Application No. 06823430.1.

Affiliated with

Also associated with

Rating

Method of treatment for ischemic heart disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treatment for ischemic heart disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for ischemic heart disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2624956